Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication

Summary: The nucleoside analog N4-hydroxycytidine (NHC) is the active metabolite of the prodrug molnupiravir, which has been approved for the treatment of COVID-19. SARS-CoV-2 incorporates NHC into its RNA, resulting in defective virus genomes. Likewise, inhibitors of dihydroorotate dehydrogenase (D...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Kim M. Stegmann, Antje Dickmanns, Natalie Heinen, Claudia Blaurock, Tim Karrasch, Angele Breithaupt, Robert Klopfleisch, Nadja Uhlig, Valentina Eberlein, Leila Issmail, Simon T. Herrmann, Amelie Schreieck, Evelyn Peelen, Hella Kohlhof, Balal Sadeghi, Alexander Riek, John R. Speakman, Uwe Groß, Dirk Görlich, Daniel Vitt, Thorsten Müller, Thomas Grunwald, Stephanie Pfaender, Anne Balkema-Buschmann, Matthias Dobbelstein
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2022-05-01
Σειρά:	iScience
Θέματα:	Virology Drugs
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2589004222005636
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!